Novavax’s Combo COVID-19 and Flu Shot Trial Reaches Key Milestone for Older Adults
Novavax (NVAX) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.
- Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter
The study, titled “A Randomized, Observer-Blinded, Active-Controlled Study to Evaluate the Safety and Immunogenicity of a COVID-19 Influenza Combination Nanoparticle Vaccine and a Standalone Trivalent Nanoparticle Influenza Hemagglutinin Vaccine in Participants ≥ 65 Years of Age,” tests a new combo shot for COVID-19 and flu in older adults. It aims to see if the shot is safe and sparks a strong immune response, which matters for Novavax’s long-term role in the seasonal respiratory vaccine market.
The main treatments are Novavax’s combo COVID-19 and flu shot, its standalone COVID-19 vaccine, its nanoparticle flu shot, and Sanofi’s Fluzone High-Dose. These products are all injected into the muscle and are meant to prevent COVID-19 and seasonal flu in people 65 and older.
The trial is a Phase 3, randomized study, which means participants are assigned by chance to one of the vaccine options. It uses a crossover model with single blinding, so participants do not know which shot they get, and the main goal is to prevent illness by checking safety and immune response.
The study was first submitted on March 1, 2024, marking the formal launch of the trial process. The most recent update was filed on June 3, 2026, and the status now shows as completed, signaling that dosing and main follow-up are finished, even though results are not yet posted.
For investors, this update supports the thesis that Novavax is pushing hard into the combined COVID-19 and flu space, a key area as annual booster markets mature. A positive readout could improve sentiment around NVAX, help offset past volatility, and position the firm against combo programs from Moderna and Pfizer, though actual stock reaction will depend on the strength and clarity of the final data.
The study is now completed and has been recently updated, with further details available on the ClinicalTrials.gov portal.
To learn more about NVAX’s potential, visit the Novavax drug pipeline page.
